Oncotarget

Research Papers:

CD39+ regulatory T cells accumulate in colon adenocarcinomas and display markers of increased suppressive function

Filip Ahlmanner _, Patrik Sundström, Paulina Akeus, Jenny Eklöf, Lars Börjesson, Bengt Gustavsson, Elinor Bexe Lindskog, Sukanya Raghavan and Marianne Quiding-Järbrink

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2018; 9:36993-37007. https://doi.org/10.18632/oncotarget.26435

Metrics: PDF 1624 views  |   HTML 2924 views  |   ?  


Abstract

Filip Ahlmanner1, Patrik Sundström1, Paulina Akeus1, Jenny Eklöf1, Lars Börjesson2, Bengt Gustavsson2, Elinor Bexe Lindskog2, Sukanya Raghavan1 and Marianne Quiding-Järbrink1

1Department of Microbiology and Immunology, The Sahlgrenska Academy at University of Gothenburg, Göteborg, Sweden

2Department of Surgery, The Sahlgrenska Academy at University of Gothenburg, Göteborg, Sweden

Correspondence to:

Filip Ahlmanner, email: [email protected]

Keywords: CD39; regulatory T cells; colon cancer; adenosine; immune checkpoint molecules

Received: March 12, 2018     Accepted: November 26, 2018     Published: December 11, 2018

ABSTRACT

Increasing knowledge of the function and regulation of tumor-infiltrating lymphocytes has led to new insights in cancer immunotherapy. Regulatory T cells (Treg) accumulate in colon tumors, and we recently showed that CD39+ Treg from cancer patients inhibit transendothelial migration of conventional T cells. CD39 mediates the hydrolysis of ATP to immunosuppressive adenosine and adds to the immunosuppressive effects of Treg. Here, we further investigated the regulatory features of intratumoral CD39+ Treg in colon cancer. Using flow cytometry analyses of cells from 46 colon cancer patients, we confirm the accumulation of CD39+ Treg in the tumor tissue compared to unaffected colon tissue, and also show that tumor-infiltrating Treg express more CD39 and Foxp3 on a per cell basis. Furthermore, CD39+ Treg in tumors express markers indicating increased turnover and suppressive ability. In particular, tumor-infiltrating CD39+ Treg have high expression of surface molecules related to immunosuppression, such as ICOS, PD-L1 and CTLA-4. Functional suppression assays also indicate potent suppressive capacity of CD39+ Treg on proliferation and IFN-γ secretion by conventional T cells. In conclusion, our results identify tumor-infiltrating CD39+ Treg as a numerous and potentially important immunosuppressive subset, and suggest that immunotherapy aimed at reducing the activity of CD39+ Treg may be particularly useful in the setting of colon cancer.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 26435